# The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies

> **NCT07023861** · EARLY_PHASE1 · ENROLLING_BY_INVITATION · sponsor: **Affiliated Hospital of Jiangnan University** · enrollment: 20 (estimated)

## Conditions studied

- Breast Cancer
- Gastric Cancer (GC)
- Urothelial Carcinoma (UC)

## Interventions

- **DRUG:** 18F-FDG
- **DRUG:** 89Zr-LNCab190
- **DRUG:** 89Zr-LNCab002
- **DRUG:** 89Zr-LNCab072

## Key facts

- **NCT ID:** NCT07023861
- **Lead sponsor:** Affiliated Hospital of Jiangnan University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-07-01
- **Primary completion:** 2026-07-07
- **Final completion:** 2026-12-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07023861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07023861, "The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07023861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*